Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Semaglutide, other obesity drugs show potential to treat nondiabetic stroke
Much more research is still required, but a new meta-analysis in Stroke suggests these medications may provide valuable stroke prevention.
Beta-blockers do not benefit heart attack patients with a normal LVEF
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
Oral heart failure drug receives FDA’s fast track designation
A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.
Winning cash for taking blood pressure meds increases compliance
About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.
$64M raised for new cardiogenic shock drug—research already underway
Procizumab was developed to change the trajectory of shock by addressing an underlying molecular driver rather than just managing symptoms.

CardiacSense, an Israel-based healthcare technology company, gained FDA clearance for its CSF-3 medical watch

Regulatory Roundup: FDA clears new medical watch, considers empagliflozin for CKD and much more

Our monthly review of FDA-related news items in the world of cardiology includes updates from CardiacSense, MedAlliance, Lupin, Realize Medical and Eli Lilly and Company.

FDA approves new medication for type 2 diabetes

The newly approved SGLT2 inhibitor, bexagliflozin, is marketed under the name Brenzavvy. It is not recommended for patients with type 1 diabetes.

Peter Libby, MD, a cardiovascular medicine specialist, Brigham and Women’s Hospital, and Mallinckrodt Professor of Medicine, Harvard Medical School, explains the take aways from the PROMINENT trial using pemafibrate to lower cardiovascular risks. The trial, presented at the American Heart Association (AHA) 2022 meeting, did not show reduction in the incidence of cardiovascular events among those who received pemafibrate than among those who received placebo. #AHA #AHA22

VIDEO: Pemafibrate does not lower cardiovascular risks in the PROMINENT trial

Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital and Harvard Medical School, explained some key takeaways from the PROMINENT trial.

How cardiologists can improve in-hospital outcomes after PCI

Researchers evaluated if two recently developed risk scores can anticipate adverse in-hospital outcomes after PCI, sharing their findings in the American Journal of Cardiology.

A new antiplatelet strategy for treating diabetic PCI patients

Clopidogrel monotherapy after just one month of DAPT was associated with promising outcomes, including a reduction in bleeding events.

VIDEO: Why does COVID-19 damage vascular beds?

Peter Libby, MD, a cardiovascular medicine specialist at Brigham and Women’s Hospital, explains his research into COVID-19 and how it damages the endothelium of blood vessels.

AI specialists ink deal with Pfizer to target cardiac amyloidosis

Cardiac amyloidosis can be especially challenging to identify and diagnose, making it a perfect target for advanced AI models.

No antithrombotic therapy after TAVR? New research highlights potential benefits

The study, published in JACC: Cardiovascular Interventions, focused on data from more than 3,500 TAVR patients.

Pharmaceutics

Semaglutide, other obesity drugs show potential to treat nondiabetic stroke

Beta-blockers do not benefit heart attack patients with a normal LVEF

Oral heart failure drug receives FDA’s fast track designation

Winning cash for taking blood pressure meds increases compliance

$64M raised for new cardiogenic shock drug—research already underway